Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
200 participants
OBSERVATIONAL
2024-08-01
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
NCT02250209
The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding
NCT02150447
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
NCT05165602
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427
Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)
NCT05361161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group
Gastirc cancer with bleeding at first diagnosis
systematic therapy
All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Control group
Gastirc cancer without bleeding at first diagnosis
systematic therapy
All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
systematic therapy
All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A histologically confirmed diagnosis of advanced or metastatic gastric cancer;
3. The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI);
4. No history of gastrectomy before systematic therapy.
Exclusion Criteria
2. Siewert I type esophagus cancer.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanhong Yao
Department of Medical Oncology and Radiation Sickness
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanhong Yao
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Yao Y, Liu Z, Zhang H, Shi X, Huang F, Zhang Y, Chen L, Shi Y, Cao B. Feasibility of systemic therapy in unresectable gastric/gastroesophageal junction cancer with overt bleeding. Asia Pac J Oncol Nurs. 2025 Jul 7;12:100750. doi: 10.1016/j.apjon.2025.100750. eCollection 2025 Dec.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00006761-M2023544
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.